Printer Friendly

LIDAK PHARMACEUTICALS APPOINTS NEW BOARD MEMBER

 LIDAK PHARMACEUTICALS APPOINTS NEW BOARD MEMBER
 LA JOLLA, Calif., Oct. 27 /PRNewswire/ -- LIDAK Pharmaceuticals


(NASDAQ: LDAKA) today announced that effective Oct. 17, 1992, Helmer P.K. Agersborg Jr., Ph.D., was named to its board of directors. Dr. Agersborg's appointment brings the number of directors to seven.
 Currently, Dr. Agersborg, 63, serves as chief executive officer and director of Afferon Corporation and Collagenex, Inc., both of Wayne, Pa. Dr. Agersborg also sits on the board of directors of International Research & Development Corporation (NASDAQ: IRDV), of Mattawan, Mich., and Pharmedic Inc. of Wheeling, Ill.
 For 32 years, Dr. Agersborg was affiliated with American Home Products Corporation (NYSE: AHP) and its wholly owned subsidiaries, Wyeth-Ayerst Research and Wyeth Laboratories. From 1987 to 1990, he served as president of Wyeth-Ayerst Research. Prior to these appointments, Dr. Agersborg was director of research for the Division of Obstetrics and Gynecology, University of Tennessee.
 Dr. Agersborg's career affiliations and honors include, among others, membership in the Society of Toxicology, the National Association for Biomedical Research; the American Society for Pharmacology and Experimental Therapeutics; chairman, PMA Safety Evaluation Subsection Steering Committee; chairman PMA R&D Section Steering Committee and PMA Foundation Scientific Advisory Committee.
 Dr. David Katz, president and chief executive officer of LIDAK Pharmaceuticals, stated, "We enthusiastically welcome Dr. Agersborg to LIDAK. His international reputation for excellence and his broad and deep pharmaceutical experience in research, planning product development and regulatory affairs, to name just a few areas, will be highly significant resource to our company."
 LIDAK Pharmaceuticals is developing pharmaceutical products for the health care industry. LIDAK is currently focusing its efforts on the commercialization of LIDAKOL(TM) as a treatment for herpes and other indications. Also, the company is developing its Large Multivalent Immunogen technology for potential new therapies against cancer and viral diseases. The company's longer-term projects include the development of proprietary technology for potential new therapeutic and diagnostic approaches to diabetes, cancer and AIDS.
 -0- 10/27/92
 /CONTACT: Michael Lorber of LIDAK, 619-558-0364, or Cathleen Mayrose of Dewe Rogerson, 212-688-6840, for LIDAK/
 (LDAKA) CO: LIDAK Pharmaceuticals ST: California IN: MTC SU: PER


CK-SM -- NY058 -- 5336 10/27/92 11:19 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 27, 1992
Words:360
Previous Article:COSTAR CORPORATION ANNOUNCES RESULTS FOR THE THIRD QUARTER 1992
Next Article:FULTON FINANCIAL CORP. REPORTS RECORD EARNINGS
Topics:


Related Articles
LIDAK PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE
LIDAK PHARMACEUTICALS ELECTS NEW DIRECTOR
LIDAK PHARMACEUTICALS APPOINTS VICE PRESIDENT OF BUSINESS DEVELOPMENT AND LICENSING
LIDAK PHARMACEUTICALS REAPPOINTS OFFICERS, APPROVES NEW CONTRACT WITH CEO AND APPOINTS CHAIRMAN
LIDAK PHARMACEUTICALS APPOINTS NEW VICE PRESIDENT AND CHIEF FINANCIAL OFFICER
LIDAK PHARMACEUTICALS COMPLETES STAFFING OF ITS CLINICAL DEVELOPMENT ADVISORY PANEL WITH ADDITION OF GALLO
LIDAK ANNOUNCES RETURN OF FORMER CHIEF FINANCIAL OFFICER
LIDAK PHARMACEUTICALS APPOINTS GERALD J. YAKATAN AS VICE PRESIDENT, DRUG DEVELOPMENT
LIDAK Pharmaceuticals Adds New Vice President and Reports Drug Development Highlights at Annual Meeting
LIDAK Pharmaceuticals Appoints Susan Yeagley Sullivan As New Chief Financial Officer

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters